Medicine

Patient information for Translation

Receiving and taking your Molnupiravir treatment for COVID-19

Name of Medicine

Molnupiravir (Lagevrio) 200mg Capsules.

Why is this medicine important for you?

It will help to reduce the risk of you being admitted to hospital or having more severe COVID-19 symptoms.

Delivering your medicines after your virtual appointment (by phone)

We will assess you over the phone and deliver your medicines directly to your home address by courier. This means you don’t have to come to the hospital to get your medicines. If your home details have changed, let us know as soon as possible.

Taking your medicines

Take your medicines according to the instructions provided.

Information on how to store your medicines in a safe place is included in the leaflet that comes with your medicines.

It is important that you complete the five-day course of this medicine even if your symptoms improve and/or you feel better, to reduce the chances of viral resistance developing.

If you are pregnant or a person of childbearing potential

There is currently no data on the use of molnupiravir in pregnancy, therefore it is not recommended during pregnancy.

If you have the potential to become pregnant, we will include a pregnancy test kit with your medication. You must take this test to rule out pregnancy before starting treatment.

If you have the potential to become pregnant, you must use effective contraception for the duration of treatment and for 4 days after the last dose of molnupiravir.

If you find out that you are pregnant, or become pregnant while taking molnupiravir, or shortly after, please report this by contacting:

UK COVID-19 Antivirals in Pregnancy Registry: 0344 892 0909 or by asking your doctor to do this on your behalf.

If you are pregnant or a person of childbearing potential

For more information go to:

medicinesinpregnancy.org/COVID19-Antivirals-Pregnancy-Registry/  

In addition, please inform your doctor as you will need to be followed up closely.

If you are Breastfeeding

If you are breastfeeding, you should stop breastfeeding during the course of treatment and for 4 days after the last dose of molnupiravir.

Side effects

Like all medicines, molnupiravir can cause side effects. Common side effects include: diarrhoea, nausea, dizziness, and headache. Most of these are mild and short term, and not everyone gets them.

Speak to your healthcare professional for advice if you are worried about your health

Check the patient information leaflet supplied with the medicine. You can also find this information on the MHRA Coronavirus Yellow Card reporting site.

Report any suspected side effects to the Yellow Card scheme using the dedicated Coronavirus Yellow Card reporting site at:

https://coronavirus-yellowcard.mhra.gov.uk

If unsure or in doubt, report it anyway. As molnupiravir is a new medicine, it is important we report all suspected adverse reactions.

Contact Us:

If you have any questions during your appointment please feel free to ask.

Should you have any question about your medicines that arise outside of your appointment, we are available to support you Monday to Friday. You can contact us via the following methods:

• Bart’s Health Hospital Covid-19 Medicines Delivery Unit (CMDU): 0208 121 4378 (9am – 6pm)
• Bart’s Health Hospital CMDU (Pharmacy):  0208 121 4364 (9am - 6pm)
• Medicines Information Patient Helpline: 0208 535 6971 (9am - 5pm)
• CMDU Patient Helpline: 07798 571707 (9am - 5pm)

Leave direct feedback about the COVID Medicines Delivery Unit (CMDU) service via the QR code below:

Large print and other languages
This information can be made available in alternative formats, such as easy read or large print, and may be available in alternative languages, upon request. For more information, speak to your clinical team.
 

এই তথ্যগুলো সহজে পড়া যায় অথবা বৃহৎ প্রিন্টের মত বিকল্প ফরম্যাটে পাওয়া যাবে, এবং অনুরোধে অন্য ভাষায়ও পাওয়া যেতে পারে। আরো তথ্যের জন্য আপনার ক্লিনিক্যাল টিমের সাথে কথা বলুন।

Na żądanie te informacje mogą zostać udostępnione w innych formatach, takich jak zapis większą czcionką lub łatwą do czytania, a także w innych językach. Aby uzyskać więcej informacji, porozmawiaj ze swoim zespołem specjalistów.

Macluumaadkaan waxaa loo heli karaa qaab kale, sida ugu akhrinta ugu fudud, ama far waa weyn, waxana laga yabaa in lagu heli luuqaado Kale, haddii la codsado. Wixii macluumaad dheeraad ah, kala hadal kooxda xarunta caafimaadka.

Bu bilgi, kolay okunurluk veya büyük baskılar gibi alternatif biçimlerde sunulabilir, ve talep üzerine Alternatif Dillerde sunulabilir. Daha fazla bilgi için klinik ekibinizle irtibata geçin.

یہ معلومات متبادل فارمیٹس میں دستیاب کی جا سکتی ہیں، جیسا کہ پڑھنے میں آسان یا بڑا پرنٹ  اور درخواست پر متبادل زبانوں میں بھی دستیاب ہو سکتی ہیں۔ مزید معلومات کے لیے، اپنی کلینکل ٹیم سے بات کریں'۔

Patient Advice and Liaison Service (PALS)

Please contact us if you need general information or advice about Trust services: www.bartshealth.nhs.uk/pals

Tell us what you think

Tweet us @NHSBartsHealth
Talk to us via facebook.com/bartshealth
Leave feedback on NHS Choices www.nhs.uk

Reference: BH/PIN/1097

Publication date: Dec 2021

All our patient information leaflets are reviewed every three years.

©Barts Health NHS Trust

Switchboard: 020 7377 7000

www.bartshealth.nhs.uk